- Home
- BXSL vs MDGL Comparison
BXSL vs MDGL Comparison
Compare BXSL & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- MDGL
- Stock Information
- Founded
- BXSL 2018
- MDGL 2011
- Country
- BXSL United States
- MDGL United States
- Employees
- BXSL N/A
- MDGL N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- BXSL Finance
- MDGL Health Care
- Exchange
- BXSL Nasdaq
- MDGL Nasdaq
- Market Cap
- BXSL 6.0B
- MDGL 7.1B
- IPO Year
- BXSL N/A
- MDGL N/A
- Fundamental
- Price
- BXSL $34.27
- MDGL $336.23
- Analyst Decision
- BXSL Strong Buy
- MDGL Buy
- Analyst Count
- BXSL 9
- MDGL 14
- Target Price
- BXSL $28.25
- MDGL $351.67
- AVG Volume (30 Days)
- BXSL 981.9K
- MDGL 357.1K
- Earning Date
- BXSL 11-08-2023
- MDGL 02-26-2025
- Dividend Yield
- BXSL 9.77%
- MDGL N/A
- EPS Growth
- BXSL N/A
- MDGL N/A
- EPS
- BXSL N/A
- MDGL N/A
- Revenue
- BXSL $491,357,000.00
- MDGL $76,813,000.00
- Revenue This Year
- BXSL $195.77
- MDGL N/A
- Revenue Next Year
- BXSL $1.83
- MDGL $195.95
- P/E Ratio
- BXSL N/A
- MDGL N/A
- Revenue Growth
- BXSL 27.36
- MDGL N/A
- 52 Week Low
- BXSL $23.82
- MDGL $189.00
- 52 Week High
- BXSL $31.64
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- BXSL 67.08
- MDGL 52.41
- Support Level
- BXSL $33.97
- MDGL $334.13
- Resistance Level
- BXSL $34.64
- MDGL $354.49
- Average True Range (ATR)
- BXSL 0.57
- MDGL 13.20
- MACD
- BXSL 0.07
- MDGL 0.16
- Stochastic Oscillator
- BXSL 79.05
- MDGL 43.12
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives through originated loans and other securities, including syndicated loans, of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, and unsecured and subordinated loans and other debt and equity securities.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.